Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00199537
Recruitment Status :
First Posted : September 20, 2005
Last Update Posted : July 29, 2008
Lawson Health Research Institute
Lawson Health Research Institute Internal Review Fund
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men with Prostate Cancer undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy
Age of 40 years or greater
Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
Willing and able to consent
Metastatic disease to bone
Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
Renal failure (serum creatinine > 200 umol/L)
Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial